AE Wealth Management LLC Acquires 3,634 Shares of Bristol-Myers Squibb Company (BMY)

AE Wealth Management LLC raised its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 65.4% during the first quarter, according to its most recent filing with the SEC. The firm owned 9,187 shares of the biopharmaceutical company’s stock after buying an additional 3,634 shares during the period. AE Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $500,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. American National Bank boosted its stake in shares of Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 508 shares in the last quarter. Welch Investments LLC raised its position in Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 79 shares during the last quarter. Crestwood Advisors Group LLC purchased a new position in Bristol-Myers Squibb during the first quarter valued at about $116,000. Blue Chip Partners Inc. raised its position in Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 17 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its position in Bristol-Myers Squibb by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 60 shares during the last quarter. 69.68% of the stock is currently owned by institutional investors.

Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at 56.42 on Friday. The stock’s 50 day moving average is $55.95 and its 200 day moving average is $54.96. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $60.45. The stock has a market cap of $92.52 billion, a PE ratio of 20.61 and a beta of 1.17. Bristol-Myers Squibb also was the recipient of unusually large options trading activity on Thursday. Stock traders bought 781 put options on the stock. This is an increase of approximately 117% compared to the average volume of 360 put options.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter in the previous year, the firm earned $0.69 earnings per share. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. Equities research analysts forecast that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th were issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 2.76%. The ex-dividend date of this dividend was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.

ILLEGAL ACTIVITY NOTICE: “AE Wealth Management LLC Acquires 3,634 Shares of Bristol-Myers Squibb Company (BMY)” was first reported by BNB Daily and is the sole property of of BNB Daily. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/ae-wealth-management-llc-raises-stake-in-bristol-myers-squibb-co-bmy-updated.html.

Several research firms recently issued reports on BMY. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 price objective on the stock in a report on Thursday. Cowen and Company set a $65.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, August 14th. Finally, Credit Suisse Group set a $58.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $62.12.

In related news, Director Theodore R. Samuels II bought 6,000 shares of the stock in a transaction dated Wednesday, August 2nd. The shares were purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the completion of the acquisition, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 0.23% of the stock is currently owned by insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply